

Orencia (abatacept)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Orencia (abatacept) – Intravenous	4 vials per 28 days*
Orencia (abatacept) – Subcutaneous	4 syringes/autojectors per 28 days

*Initiation of intravenous therapy for Rheumatoid Arthritis (RA), Polyarticular Juvenile Idiopathic Arthritis (PJIA), or Psoriatic arthritis (PsA): May approve 4 (four) additional vials (250 mg/vial) in the first 28 days (4 weeks) of treatment. For Graft Versus Host Disease (GVHD): May approve up to 4 vials (250 mg/vial) per infusion for a total of 4 (four) infusions starting the day before transplantation (day -1), followed by administration on days 5, 14, and 28 after transplantation.

APPROVAL CRITERIA

Initial requests for Orencia (abatacept) may be approved if the following criteria are met:

- I. Rheumatoid arthritis (RA) when each of the following criteria are met:
 - A. Individual is 18 years of age or older with moderate to severe RA;
 - AND**
 - B. Individual has had an inadequate response to methotrexate titrated to maximally tolerated dose (ACR 2021); **OR**
 - C. If methotrexate is not tolerated, individual has had an inadequate response to or is intolerant of other conventional therapy (sulfasalazine, leflunomide, hydroxychloroquine); **OR**
 - D. Individual has a contraindication to methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine;
 - AND**
 - E. Documentation is provided that individual has had a trial and inadequate response or intolerance to TWO (2) preferred agents [Current preferred agents include – preferred adalimumab (Reference product Humira), Enbrel (etanercept), or Simponi (golimumab)]*. A trial of multiple products with the same active ingredient counts as a trial of ONE preferred agent. Medication samples/coupons/discount cards are excluded from consideration as a trial.;
 - AND**
 1. Documentation is provided describing the nature of the inadequate response or intolerance for each product tried;
 - OR**
 2. Documentation is provided that a completed FDA MedWatch Adverse Event Reporting Form has been submitted to the FDA for each product tried;

OR

- F. Documentation is provided that is currently on Orencia (abatacept). Medication samples/coupons/discount cards are excluded from consideration as a trial; **OR**
- G. Documentation is provided that individual is unable to use the preferred agents due to:
 - 1. demyelinating disease or heart failure with documented left ventricular dysfunction;

OR

- H. Documentation is provided for why the individual is unable to use ALL preferred agents (or all remaining preferred agents if individual has tried any preferred agent) due to one of the following:
 - 1. The individual is subject to a warning or contraindication that appears in the labeling of ALL preferred products and is not included in the labeling of Orencia (abatacept); **OR**
 - 2. None of the preferred products have activity against the individual's concomitant clinical condition which is covered by Orencia (abatacept);

*Note: Rinvoq is the preferred Janus Kinase (JAK) inhibitor.

OR

- II. Polyarticular juvenile idiopathic arthritis (PJIA) when each of the following criteria are met:
 - A. Individual has moderate to severe PJIA; **AND**
 - B. Individual is 6 years of age or older for administration of intravenous infusion;**OR**
 - C. Individual is 2 years of age and older for administration of subcutaneous injection;**AND**
 - D. Individual has had an inadequate response too or is intolerant of conventional therapy [nonbiologic disease modifying antirheumatic drugs (DMARDs) (such as methotrexate) (ACR 2019); **OR**
 - E. Individual has a contraindication to methotrexate;

AND

- F. Documentation is provided that individual has had a trial and inadequate response or intolerance to TWO (2) preferred agents [Current preferred agents include – preferred adalimumab (Reference product Humira), and Enbrel (etanercept)]. A trial of multiple products with the same active ingredient counts as a trial of ONE preferred agent. Medication samples/coupons/discount cards are excluded from consideration as a trial.;

AND

- 1. Documentation is provided describing the nature of the inadequate response or intolerance for each product tried;
- OR**
- 2. Documentation is provided that a completed FDA MedWatch Adverse Event Reporting Form has been submitted to the FDA for each product tried;

OR

- G. Documentation is provided that individual is currently on Orenzia (abatacept). Medication samples/coupons/discount cards are excluded from consideration as a trial.;
- H. Documentation is provided that the individual has either concomitant clinical condition:
1. Demyelinating disease; **OR**
 2. Heart failure with documented left ventricular dysfunction;

OR

- I. Documentation is provided for why the individual is unable to use ALL preferred agents (or all remaining preferred agents if individual has tried any preferred agent) due to one of the following:
1. The individual is subject to a warning or contraindication that appears in the labeling of ALL preferred products and is not included in the labeling of Orenzia (abatacept); **OR**
 2. None of the preferred products have activity against the individual's concomitant clinical condition which is covered by Orenzia (abatacept);

OR

- III. Psoriatic arthritis (PsA) when each of the following criteria are met:
- A. Individual is 2 years of age or older with moderate to severe PsA; **AND**
 - B. Individual has had an inadequate response to or is intolerant of conventional therapy [nonbiologic disease modifying anti-rheumatic drugs (DMARDs) (such as methotrexate, sulfasalazine, cyclosporine, or leflunomide)] (ACR 2019); **OR**
 - C. Individual has a contraindication to methotrexate, sulfasalazine, cyclosporine, and leflunomide;

AND

- D. Documentation is provided that individual has had a trial and inadequate response or intolerance to TWO (2) preferred agents [Current preferred agents include – preferred adalimumab (Reference product Humira), Cosentyx (secukinumab), Enbrel (etanercept), Otezla (apremilast), Simponi (golimumab), Skyrizi (Risankizumab-rzaa), Stelara (ustekinumab), Tremfya (guselkumab)^]. A trial of multiple products with the same active ingredient counts as a trial of ONE preferred agent. Medication samples/coupons/discount cards are excluded from consideration as a trial.;

AND

1. Documentation is provided describing the nature of the inadequate response or intolerance for each product tried;

OR

2. Documentation is provided that a completed FDA MedWatch Adverse Event Reporting Form has been submitted to the FDA for each product tried;

OR

- E. Documentation is provided that individual is currently on Orenzia (abatacept). Medication samples/coupons/discount cards are excluded from consideration as a trial.

OR

- F. Documentation is provided for why the individual is unable to use ALL preferred agents (or all remaining preferred agents if individual has tried any preferred agent) due to one of the following:

1. The individual is subject to a warning or contraindication that appears in the labeling of ALL preferred products and is not included in the labeling of Orencia (abatacept); **OR**
2. None of the preferred products have activity against the individual's concomitant clinical condition which is covered by Orencia (abatacept);

OR

- III. Acute Graft Versus Host Disease (GVHD), prophylaxis, when each of the following criteria are met:
- A. Individual is 2 years of age or older using for prophylaxis of acute GVHD; **AND**
 - B. Individual will be undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor; **AND**
 - C. Individual is using Orencia (abatacept) in combination with a calcineurin inhibitor and methotrexate;

OR

- IV. Chronic Graft-versus-host disease (GVHD) when each of the following criteria are met (NCCN 2A):

- A. Individual has a diagnosis of steroid-refractory chronic GVHD; **AND**
- B. Individual is initiating abatacept in combination with systemic corticosteroids;

OR

- V. Immune checkpoint inhibitor therapy-related toxicities when each of the following criteria are met (NCCN 2A):
- A. Individual is undergoing immune checkpoint inhibitor therapy for a cancer diagnosis; **AND**
 - B. Individual is experiencing immunotherapy-related myocarditis; **AND**
 - C. Myocarditis is unresponsive to high-dose systemic corticosteroids.

Continuation requests for Orencia (abatacept) may be approved if the following criterion is met:

- I. Documentation is provided that individual has been receiving and is maintained on a stable dose of Orencia. Medication samples/coupons/discount cards are excluded from consideration as a trial.; **AND**
- II. There is clinically significant improvement or stabilization in clinical signs and symptoms of the disease.

Requests for Orencia (abatacept) may **not** be approved for the following:

- I. In combination with topical or oral JAK inhibitors, ozanimod, etrasimod, apremilast, deucravacitinib, or any of the following biologic immunomodulators: TNF antagonists, IL-23 inhibitors, IL-17 inhibitors, vedolizumab, ustekinumab, IL-1 inhibitors, IL-6 inhibitors, rituximab or natalizumab; **OR**
- II. Tuberculosis or other active serious infections or a history of recurrent infections [repeat testing not required for ongoing authorization]; **OR**
- III. If initiating therapy, individual has not had a tuberculin skin test (TST) or Centers for Disease Control (CDC-) and Prevention - recommended equivalent test to evaluate for latent tuberculosis (unless switching therapy from another targeted immune modulator and no new risk factors) **OR**
- IV. When the above criteria are not met and for all other indications.

^Note – Trial of preferred products does not apply in states where not on formulary. Tremfya (guselkumab) non-formulary (NY).

Key References:

1. Centers for Disease Control and Prevention (CDC). Tuberculosis (TB). Available at: https://www.cdc.gov/tb/risk-factors/?CDC_AAref_Val=https://www.cdc.gov/tb/topic/basics/risk.htm.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 1, 2025.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2025; Updated periodically.
5. Fraenkel L, Bathon JM, England BR et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care & Research*. 2021;73(7):924-939.
6. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. *Arthritis Rheum*. 2019; 71(1): 5-32.
7. Ringold S, Weiss PF, Beukelman T, et al. 2013 Update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. *Arthritis Rheum*. 2013; 65(10):2499-2512.
8. Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Entesitis. *Arthritis Rheum*. 2019; 71(6):846-863.
9. Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. *Arthritis Rheum*. 2022; 74(4):553-569.
10. NCCN Clinical Practice Guidelines in Oncology™. © 2025 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on October 1, 2025.
 - a. Management of Immunotherapy-related Toxicities. V1.2025. Revised December 20, 2024.
 - b. Hematopoietic Cell Transplantation. V3.2025. Revised September 24, 2025.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.